FDA accepts Alzheimer's candidate aducanumab for priority review

10 August 2020
brain_alzheimer_credit_depositphotos_large

Shares of US biotech major Biogen (Nasdaq: BIIB) rose 12% to $310 in early trading on Friday, after the company announced that the US Food and Drug Administration has accepted for priority review the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.

Under the priority review, a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2021, has been set, and the FDA said that, if possible, it plans to act early on this application under an expedited review. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes. Biogen stated that it did not use its Priority Review voucher and that the status was granted by the FDA on gratis basis.

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement in 2010. Since October 2017, Biogen and Japanese drugmaker Eisai (TYO: 4523) have collaborated on the development and commercialization of aducanumab globally.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology